AC
MNTA

Armistice Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Armistice Capital’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-132,000
Closed -$2.44M – 86
2017
Q3 		$2.44M Sell
132,000
-688,000
-84% -$11.5M 0.29% 57
2017
Q2 		$13.9M Buy
+820,000
New +$12.5M 1.77% 19

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Armistice Capital's MNTA Position: Q4 2017 in Review

Armistice Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2017, closing a stake of 132,000 shares — an estimated $2.44M sold.

Armistice Capital first reported a position in MNTA in Q2 2017 and held it in 2 quarters. The position peaked at $13.9M in Q2 2017. 166 funds tracked by Wall St. Rank hold MNTA as of Q4 2017.

  • Armistice Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Armistice Capital sold 132,000 Momenta Pharmaceuticals, Inc. shares in Q4 2017, an estimated $2.44M.
  • Armistice Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
  • Armistice Capital's Momenta Pharmaceuticals, Inc. position peaked at $13.9M in Q2 2017.
  • 166 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2017.

Based on Armistice Capital's 13F filing for Q4 2017, filed 14 Feb 2018.